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Abstract
Background: Breast cancer is the most common cause of cancer death among women. Several studies have
investigated the relationship between the C3435T polymorphism of ABCB1 gene and risk of breast cancer; but
the results are conflicting. In the present study, we sought to assess the relationship between the C3435T
polymorphism in ABCB1 gene and the risk of breast cancer in a sample of the Moroccan population.
Methods: A case control study was performed on 60 breast cancer patients and 68 healthy women. The ABCB1
C3435T polymorphism was analyzed by polymerase chain reaction-restriction fragment length polymorphism
(PCR-RFLP) assay. Furthermore, a meta-analysis including 16 studies with 6094 cases of breast cancer and 8646
controls was performed.
Results: Genotype frequencies were 50 % for CC, 33.3 % for CT and 16.7 % for TT in patients and 41.2 % for CC,
48.5 % for CT and 10.3 % for TT respectively in the control group. This difference was not statistically significant.
The same trend as observed in the allele distribution between patients and controls (P = 0.84). Findings from the
meta-analysis showed that the ABCB1 C3435T polymorphism was not associated with an increased risk of breast cancer
in the dominant model (OR = 0.907; 95 % CI = 0.767–1.073; P = 0.25) as well as in the recessive model (OR = 1.181; 95 %
CI = 0.973–1.434; P = 0.093) and in the allele contrast model (OR = 1.098; 95 % CI = 0.972–1.240; P = 0.133). However,
the stratification of studies on ethnic basis showed that the TT genotype was associated with the risk of breast cancer
in Asians (OR = 1.405; 95 % CI = 1.145–1.725; P = 0.001), Caucasians (OR = 1.093; 95 % CI = 1.001–1.194; P = 0.048) and
North African (OR = 2.028; 95 % CI = 1.220–3.371; P = 0.006).
Conclusions: We have noted that the implication of C3435T variant on the risk of breast cancer was ethnicity-
dependent. However, there is no evidence that ABCB1 C3435T polymorphism could play a role in susceptibility
to breast cancer in Morocco. Further studies with a larger sample size, extended to other polymorphisms are
needed to understand the influence of ABCB1 genetic variants on the risk of breast cancer.
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Background
Breast cancer is the most common cause of cancer death
among women and the most frequently diagnosed
female cancer [1]. In Morocco, the cancer registries
implemented in Rabat and Casablanca have reported a
standardized incidence of 39.9 and 49.2 per 100,000
women respectively [2, 3].
The etiology of this disease is not fully understood,
although many risk factors have been identified, such as
hormonal, environmental and lifestyle factors. In addition,
some molecular markers have been found to be associated
with the risk of breast cancer. The human multidrug re-
sistance gene 1 (MDR1/ABCB1), localized to chromosome
region 7q21, encodes P-glycoprotein (P-gp) a transmem-
brane transport protein of 170 kDa that acts as an adeno-
sine triphosphate-dependent efflux transporter pump [4].
This protein is expressed in most human tissues such as
intestine, liver, bile, kidney, adrenal gland, placenta, brain
and breast. It allows the cells to eliminate hydrophobic
substrates and anti-cancer drugs [5–7].
To date, thousands of SNPs have been identified in the
ABCB1 gene. One of the most important ABCB1 gene
polymorphism is 3435C > T (rs1045642) in exon 26, a
synonymous polymorphism witch alters gene expression,
protein activity and substrate specificity [8–10]. Indeed,
subjects with the TT genotype showed a decreased
intestinal P-gp expression compared to CC genotype
carriers [11].
Several studies have investigated the relationship be-
tween the C3435T polymorphism in ABCB1 gene and
the risk of breast cancer in different populations, how-
ever the results are inconsistent and the relevance of this
polymorphism remains confusing [12–26].
To the best of our knowledge, the relationship between
the C3435T polymorphism of ABCB1 gene and the risk of
breast cancer has not been examined in the Moroccan
population. In this manuscript we evaluated the possible
influence of ABCB1 C3435T polymorphism on the sus-
ceptibility of breast cancer as well as its correlation with
the clinical features of Moroccan patients with breast can-
cer. Secondly, we carried out a meta-analysis on 16 studies
involving 6,094 cases of breast cancer and 8,646 controls
in order to widely estimate the relationship between this
polymorphism and breast cancer risk.
Methods
Study population
The present study was performed on 60 unrelated pa-
tients with histologically confirmed breast cancer treated
between 2009 and 2010 at Mohammed VI Center for
Cancer Treatment, Ibn Rochd University Hospital of
Casablanca, Morocco. The control group consisted of 68
healthy women without a history of breast or other can-
cers. The general characteristics of the patients, including
age of menarche, age of first pregnancy, number of preg-
nancies, breastfeeding, oral contraceptives use, the num-
ber of abortions, menopause status, smoking status, body
mass index (BMI) and family history of breast cancer were
collected through structured survey forms. Clinical and
pathological features including age at diagnosis, histology
type, tumor size, Scarff-Bloom-Richardson (SBR) grade,
lymph nodes status and hormone receptor status were
obtained from medical records.
The study was approved by the local ethics committee
and written informed consent was obtained from each
participant.
Genotyping
Genomic DNA was extracted from peripheral blood
using the salting out method [27]. The ABCB1 C3435T
polymorphism was analyzed by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP)
assay using the primer sequences 5′-TTGATGGCAAAG
AAATAAAGC-3′ and 5′-CTTACATTAGGCAGTGAC
TCG-3′. The PCR reaction was performed in a total vol-
ume of 25 μl containing 100 ng of genomic DNA, 1× of
5× GoTaq Flexi Buffer (Promega), 1.25 mM MgCl2,
0.2 mM of each dNTP, 0.625 mM of each primer and
0.5U Go Taq DNA polymerase (Promega). PCR program
consisted of an initial denaturation at 94 °C for 5 min
followed by 35 cycles of 95 °C for 90 s, 55 °C for 60 s,
72 °C for 90 s, and a final extension at 72 °C for 7 min.
Controls with known genotypes (homozygous wild-type,
homozygous mutant, and heterozygous) were included
in each PCR as a reference. PCR products were digested
with 10 units of Mbo I restriction enzyme for 16 h. The
digested products were separated by 3 % agarose gel
electrophoresis after ethidium bromide staining and ob-
served under UV light. The resulting fragments were
130 bp and 76 bp for the Wild-type homozygote CC,
206 bp, 130 bp and 76 bp for the heterozygote CT and
206 bp for Homozygote mutant variant TT.
Meta-analysis
A literature search of online databases (PubMed,
Embase, Scopus, EBSCO…) was conducted until April 1,
2016 using appropriate keywords: “MDR1”, “ABCB1”,
“C3435T polymorphism” and “breast cancer”. All lan-
guages were searched initially, but only English language
studies were selected.
The following criteria were used to select the eligible
studies: (a) a case-control study on the association be-
tween ABCB1 C3435T polymorphism and breast cancer
risk, (2) have an available genotype or allele frequency,
and odds ratio (OR) with 95 % confidence interval (CI).
Major exclusion criteria were (a) case-only study and
review articles and (b) studies without raw data of the
C3435T ABCB1 genotypes.
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Statistical analysis
Statistical analysis was performed using SPSS 19.0 soft-
ware. The chi-squared (χ2) test was used to assess the
Hardy-Weinberg equilibrium in genotype distribution.
OR with 95 % CI was used to assess the strength of the
association between ABCB1 C3435T polymorphism and
breast cancer risk. Student’s t-test and Fisher exact test
were used to evaluate the correlation between the
studied polymorphism and the clinicopathological pa-
rameters. All tests were two-sided and a p value less
than 0.05 were considered as statistically significant.
The meta-analysis was performed by MedCalc v.11.6.1.0
software. OR with 95 % CI was used to assess the associ-
ation between the ABCB1 C3435T polymorphism and
breast cancer risk. Genetic heterogeneity was tested by
Cochran’s (Q) test [28]. Random-effects model was used
when the P value of heterogeneity test is less than 0.05;
otherwise, fix-effects model was used.
Results
The general characteristics of breast cancer patients with-
out any history of smoking are summarized in Table 1. The
mean age at diagnosis was 41.5 ± 10.4 years. Mean of BMI
was 26.2 kg/m2 (range 16.6–43.6 kg/m2). The mean age of
menarche was 13.5 years old (range 10–18 years) and the
mean age of menopause was 48.5 ± 4.9 years old (range
40–59 years). 63.3 % of patients had descendants (2.9 ± 1.6
children), 79.5 % of them breastfeed (22.6 months, range
1–72). Finally, 48.3 % of patients presented a family history
of breast cancer. The hormone replacement therapy has
not been used by post-menopausal women.
Allele and genotype frequencies of ABCB1 C3435T
polymorphism in breast cancer patients and controls are
summarized in Table 2. In breast cancer patients, the
CC genotype was found in 50 %, CT genotype was found
in 33.3 % and TT genotype was found in 16.7 %. In the
control group, the frequencies of genotypes were 41.2 %
for CC, 48.5 % for CT and 10.3 % for TT. This difference
was not statistically significant. The genotype distributions
among cases and controls were in Hardy-Weinberg
equilibrium (χ2 = 3.75, P = 0.05 for patients and χ2 =
0.36, P = 0.55 for controls). The allele frequencies in
breast cancer patients and healthy controls were 66.7
and 65.4 % for C allele, and 33.3 and 34.6 % for T allele,
respectively (OR = 0.95; 95 % CI = 0.56–1.59; P = 0.84).
The ABCB1 C3435T polymorphism was not signifi-
cantly associated with increased risk of breast cancer in
the additive, dominant and recessive models.
Table 3 shows the potential association between the
C3435T genetic variant and risk factors of breast cancer
in patients. There was no evidence of a significant asso-
ciation between this polymorphism and risk factors of
breast cancer (P > 0.05).
Clinical and pathological characteristics of breast can-
cer patients, according to ABCB1 genotypes are shown
in Table 4. Our data suggest that there is no significant
association between the ABCB1 C3435T polymorphism
and age at diagnosis, menopausal status, histology type,
tumor size, SBR grade, lymph node status and hormone
receptor status (P > 0.05).
Concerning the meta-analysis, the characteristics of the
selected studies are summarized in Table 5. Our findings
showed no significant association between C3435T poly-
morphism of ABCB1 and the risk of breast cancer in
the dominant model (OR = 0.907; 95 % CI = 0.767–1.073;
P = 0.25) as well as the recessive model (OR = 1.181;
95 % CI = 0.973–1.434; P = 0.093), and the allele contrast
model (OR = 1.098; 95 % CI = 0.972–1.240; P = 0.133)
(Table 6; Fig. 1).
Table 1 General characteristics of Moroccan breast cancer
patients included in the case–control study
Characteristics Mean ± SD
Age (years) 41.5 ± 10.4
BMI (kg/m2) 26.2 ± 5.5
Age at menarche (years) 13.5 ± 1.7
Age at first birth (years) 23.4 ± 6.1
Number of children 2.9 ± 1.6
Age at menopause (years) 48.5 ± 4.9
Mean (range)
Median age at diagnosis (years) 38.5 (25–67)
N (%)
Nulliparous 22 (36.7)
BMI body mass index, SD standard deviation, N number, % percentage
Table 2 Genotype distribution and allelic frequencies of ABCB1
C3435T polymorphism among Moroccan breast cancer cases
and healthy controls
Variable Cases (%) Controls (%) OR (95 % CI) P value
Genotypes
CC 30 (50.0) 28 (41.2) Reference
CT 20 (33.3) 33 (48.5) 0.57 (0.27–1.21) 0.14
TT 10 (16.7) 7 (10.3) 1.33 (0.44–3.98) 0.61
Dominant model
CC 30 (50.0) 28 (41.2) Reference
CT + TT 30 (50.0) 40 (58.8) 0.7 (0.35–1.41) 0.37
Recessive model
CC + CT 50 (83.3) 61 (89.7) Reference
TT 10 (16.7) 7 (10.3) 1.74 (0.62–4.91) 0.31
Alleles
C 80 (66.7) 89 (65.4) Reference
T 40 (33.3) 47 (34.6) 0.95 (0.56–1.59) 0.84
% percentage, OR Odd Ratio, CI Confidence Interval, CC homozygous wild-type,
CT heterozygous, TT homozygous mutant
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A significant correlation was observed between breast
cancer risk and C3435T polymorphism in the recessive
model (P = 0.008) and in the allele contrast model (P =
0.017) under the fixed-effects model. However, we ob-
served heterogeneity among the total studies in the re-
cessive model (I2 = 62.01 %; P = 0.0005), in the dominant
model (I2 = 57.35 %; P = 0.0023) and in the allele contrast
model (I2 = 69.04 %; P < 0.0001). This explains the use of
the random effects model in all these cases.
To identify the potential source of the significant
heterogeneity observed in the overall population, we
performed a subgroup analysis based on ethnicity. The
results showed an increased risk of breast cancer among
Asians (OR = 1.405; 95 % CI = 1.145–1.725; P = 0.001),
Caucasians (OR = 1.093; 95 % CI = 1.001–1.194; P = 0.048)
and North African (OR = 2.028; 95 % CI = 1.220–3.371;
P = 0.006) with the TT genotype under the recessive model.
Nevertheless, no significant association was found in mixed
populations. We noted a significant association with breast
cancer risk in the homozygote and allele contrast models
for North Africans and Asians populations carrying the TT
genotype and T allele (Table 7).
Discussion
ABCB1 gene is a member of the ABC family that en-
codes P-gp protein, which is an ATP-dependent efflux
pump that allows the cells to eliminate toxins and car-
cinogenic substances [6]. Some reports suggested that
Table 3 Association between ABCB1 C3435T genotypes and breast cancer risk factors in Moroccan patients
Variable Total C3435T polymorphism genotypes P
valueCC (%) CT (%) TT (%)
BMI 60
<22 kg/m2 17 11 (64.7) 4 (23.5) 2 (11.8) 0.36
≥22 kg/m2 43 19 (44.2) 16 (37.2) 8 (18.6)
Age of menarche (years) 60
<13 16 9 (56.25) 4 (25.0) 3 (18.75) 0.71
≥13 44 21 (47.7) 16 (36.4) 7 (15.9)
Age of first pregnancy (years) 40
<25 23 11 (47.8) 8 (34.8) 4 (17.4) 0.08
≥25 17 10 (58.8) 1 (5.9) 6 (35.3)
Number of pregnancies 60
≤1 30 14 (46.7) 12 (40.0) 4 (13.3) 0.51
>1 30 16 (53.3) 8 (26.7) 6 (20.0)
Number of abortions 60
≤1 55 28 (50.9) 19 (34.5) 8 (14.5) 0.34
>1 5 2 (40.0) 1 (20.0) 2 (40.0)
Oral contraceptives use 60
Yes 35 18 (51.4) 10 (28.6) 7 (20.0) 0.56
No 25 12 (48.0) 10 (40.0) 3 (12.0)
Family history of breast cancer 60
Yes 29 14 (48.3) 8 (27.6) 7 (24.1) 0.29
No 31 16 (51.6) 12 (38.7) 3 (9.7)
Age group (years) 60
≤40 34 20 (58.8) 10 (29.4) 4 (11.8) 0.25
>40 26 10 (38.5) 10 (38.5) 6 (23.1)
Menopausal status 60
Premenopausal 40 22 (55.0) 11 (27.5) 7 (17.5) 0.26
Postmenopausal 20 8 (40.0) 9 (45.0) 3 (15.0)
Breastfeeding 60
Yes 31 17 (54.8) 8 (25.8) 6 (19.4) 0.43
No 29 13 (44.8) 12 (41.4) 4 (13.8)
BMI body mass index, CC homozygous wild-type, CT heterozygous, TT homozygous mutant, % percentage
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this polymorphism may influence the risk of a number
of cancers, especially breast carcinoma [29]. Indeed, this
synonymous mutation (Ile1145Ile) influences protein
stability [30] and causes cellular damage or apoptosis
alteration witch play an important role in cancer devel-
opment due to an accumulation of metabolites within
the cell [31, 32].
In the present study, we have evaluated the association
between the genetic polymorphism C3435T of ABCB1
gene and the risk of breast cancer among Moroccan pa-
tients. In agreement with a number of previous reports
[16, 18, 21, 23, 24], our findings revealed no significant
association between this polymorphism and breast can-
cer development. Otherwise, Gutierrez-Rubio et al. [24]
did not find differences in the distribution of C3435T
polymorphism between breast cancer patients and con-
trols. However, when they have examined the associ-
ation between this polymorphism and breast cancer
risk, according to the menopausal status of patients,
they found that premenopausal women with T allele
have 2-fold increased risk of breast cancer.
In contrast, other studies have reported different re-
sults. Most of these findings reported the association of
TT genotype and T allele with high risk of breast cancer.
Turgut et al. [13] revealed a 1.5-fold increased risk for
the development of breast cancer in T allele carriers.
Similarly, Cizmarikova et al. [17] and George et al. [15]
have found a significantly higher prevalence of T allele
and TT genotype in breast cancer patients when com-
pared to controls (P = 0.019 and P = 0.025 respectively).
Furthermore, Wu et al. [20] conducted a large study
with 1,173 breast cancer women and 1,244 controls and
reported a significant increase in the frequency of the TT
genotype (TT vs. CC: OR = 1.386; 95 % CI = 1.091–1.761;
P = 0.008) and T allele (OR = 1.281; 95 % CI = 1.021–
1.285; P = 0.020) in patients with breast cancer. More
recently, Fawzy et al. [22] studied 190 Egyptian females
with breast cancer and showed that the frequency of the
TT genotype (OR = 1.45; 95 % CI = 1.09–1.94; P = 0.01)
and T allele (OR = 2.41; 95 % CI = 1.27–4.56; P = 0.0006)
were significantly higher in breast cancer patients com-
pared to healthy controls.
Table 4 Association between ABCB1 C3435T genotypes and clinico-pathological characteristics of breast cancer in Moroccan
patients
Variable Total C3435T polymorphism genotypes P
valueCC (%) CT (%) TT (%)
Histology 60
IDC 54 26 (48.1) 19 (35.2) 9 (16.7) 0.44
ILC 3 1 (33.3) 1 (33.3) 1 (33.3)
Others 3 3 (100.0) - -
Tumor size 60
T1 7 2 (28.6) 3 (42.9) 2 (28.6) 0.41
T2 29 15 (51.7) 8 (27.6) 6 (20.7)
T3 11 8 (72.7) 3 (27.3) -
T4 13 5 (38.5) 6 (46.2) 2 (15.4)
SBR 60
I 3 2 (66.7) - 1 (33.3) 0.61
II 45 23 (51.1) 16 (35.6) 6 (13.3)
III 12 5 (41.7) 4 (33.3) 3 (25.0)
Node involvement 60
N- 25 13 (52.0) 7 (28.0) 5 (20.0) 0.78
N+ 34 17 (50.0) 12 (35.2) 5 (14.7)
Progesterone receptors status 60
PR- 27 16 (59.3) 8 (29.6) 3 (11.1) 0.38
PR+ 33 14 (42.4) 12 (36.4) 7 (21.2)
Estrogen receptors status 60
ER- 22 14 (63.6) 5 (22.7) 3 (13.6) 0.27
ER+ 38 16 (42.1) 15 (39.5) 7 (18.4)
CC homozygous wild-type, CT heterozygous, TT homozygous mutant, % percentage, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, SBR Scarff–
Bloom–Richardson, ER estrogen receptor, PR progesterone receptor
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Table 5 Main characteristics of individual studies included in the meta-analysis on ABCB1 C3435T polymorphism and breast cancer risk






Genotypes (N) Alleles (N) Genotypes (N) Alleles (N)
CC CT TT C T CC CT TT C T
Tazzite et al. 2016 (current paper) Morocco North Africa 60/68 PCR-RFLP 30 20 10 80 40 28 33 7 89 47 0.55
Abuhaliema et al. 2016 [26] Jordan Middle East 150/150 PCR-RFLP 68 62 20 198 102 40 65 45 145 155 0.11
Ghafouri et al. 2015 Iran Caucasian 100/200 PCR-RFLP 75 16 9 166 34 141 50 9 332 68 0.11
Gutierrez-Rubio et al. 2015 [24] Mexico Mixed 248/152 PCR-RFLP 82 133 33 297 199 56 72 24 184 120 0.91
Macías-Gómez et al. 2014 [23] Mexico Mixed 64/183 PCR-RFLP 15 41 8 71 57 37 103 43 177 189 0.09
Fawzy et al. 2014 [22] Egypt North Africa 190/190 ARMS-PCR 60 92 38 212 168 76 94 20 246 134 0.25
Rubis et al. 2012 [21] Poland Caucasian 209/205 PCR-RFLP 48 96 65 192 226 52 103 50 207 203 0.94
Wu et al. 2012 [20] China Asian 1,173/1,244 PCR-RFLP 388 565 220 1,341 1,005 440 624 180 1,504 984 0.08
Abbas et al. 2010 [19] Germany Caucasian 3,148/5,486 MALDI-TOF MS 703 1,543 902 2,949 3,347 1,228 2,736 1,522 5,192 5,780 0.98
Taheri et al. 2010 [18] Iran Caucasian 54/50 PCR-RFLP 10 30 14 50 58 10 27 13 47 53 0.55
Cizmarikova et al. 2010 [17] Slovak Caucasian 221/113 PCR-RFLP 46 108 67 200 242 35 54 24 124 102 0.71
Tatari et al. 2009 [16] Iran Caucasian 106/77 PCR-RFLP 16 57 33 89 123 12 45 20 69 85 0.11
George et al. 2009 [15] India Asian 86/68 PCR-RFLP 8 39 39 55 117 15 32 21 62 74 0.67
Henriquez-Hernandez et al. 2009 [14] Spain Caucasian 135/301 PCR-RFLP 35 70 30 140 130 85 162 54 332 270 0.13
Turgut et al. 2007 [13] Turkey Caucasian 57/50 PCR-RFLP 7 33 17 47 67 18 23 9 59 41 0.73
Nordgard et al. 2007 [12] Norway Caucasian 93/109 PCR-RFLP 9 51 33 69 117 17 52 40 86 132 0.99
N number, CC homozygous wild-type, CT heterozygous, TT homozygous mutant, PCR-RFLP Polymerase chain reaction-restriction fragment length polymorphism, ARMS-PCR Amplification refractory mutation












Counterwise, a recent study of Abouhalima et al. [26]
among Jordanian women have revealed a higher prevalence
of CC genotype in breast cancer patients compared to con-
trols (P < 0.001) and individuals with T allele were 2 times
less likely to develop breast cancer (P < 0.0001). It should be
noted that in a study of Salem et al., the T allele was more
prevalent among Jordanians than the C allele [33]. On the
other hand, the authors suggested strong linkage disequilib-
rium with other polymorphisms in ABCB1 gene and alter-
ations in the post translational pathway which influences
the efficacy and stability of P-gp in patients with CC geno-
type [26]. Similarly, in Kurdish patients the frequency of CC
genotype and C allele were higher in patients than in
controls; this result was not statistically significant [25].
These conflicting results may be due to the ethnicity
and the environment of the studied population, the ana-
lysis type and the sample size. Indeed, it was reported
that the distribution of C3435T genotypes varies among
populations [33–35]. In Caucasians, the C3435T genotype
frequency was 22, 50 and 28 % for CC, CT and TT geno-
types respectively [36]. In Morocco, genotype frequencies
were 39 % for CC, 51 % for CT and 10 % for TT [37].
Besides, we did not find a significant difference in the
distribution of breast cancer risk factors among CC, CT
and TT genotypes. Similar to our results, Tatari et al.
reported an absence of association between C3435T ge-
notypes of ABCB1 gene and the risk factors, including
age of disease onset, cancer stage, family history of the
cancer, smoking history, age of menarche, age of first
pregnancy, number of pregnancies, abortion history, and
history of oral contraceptive consumption (P > 0.05)
[16]. Also, Wu et al. have reported no statistically signifi-
cant correlation between genotype distributions and age
at diagnosis, menopausal state and family history of
breast carcinoma [20].
The correlation between the clinical and pathological
features of breast cancer in the present study, according
to C3435T polymorphism genotypes revealed no signifi-
cant association at this level. In this line, Turgut et al.
[13], Wu et al. [20] and Macías-Gómezdid et al. [23]
have reported similar results. However, Ghafouri et al.
have found a significant correlation between ABCB1
C3435T polymorphism and clinical grades of breast
cancer with higher grade in CC carriers (P = 0.027) [25].
Table 6 Pooled analysis for the association between ABCB1 C3435T polymorphism and breast cancer risk
Study Dominant model
CC vs. TT + CT
Recessive model
TT vs. CC + CT
Allele contrast model
T vs. C
OR 95 % CI P value OR 95 % CI P value OR 95 % CI P value
Tazzite et al. 2016 (current paper) 1.429 0.710 to 2.875 1.743 0.619 to 4.910 0.947 0.564 to 1.590
Abuhaliema et al. 2016 [26] 2.280 1.405 to 3.700 0.359 0.200 to 0.645 0.482 0.347 to 0.670
Ghafouri et al. 2016 [25] 1.255 0.728 to 2.165 2.099 0.806 to 5.466 1.000 0.636 to 1.571
Gutierrez-Rubio et al. 2015 [24] 0.847 0.555 to 1.292 0.819 0.463 to 1.447 1.027 0.767 to 1.375
Macías-Gómez et al. 2014 [23] 1.208 0.611 to 2.388 0.465 0.206 to 1.052 0.752 0.502 to 1.127
Fawzy et al. 2014 [22] 0.692 0.454 to 1.055 2.125 1.185 to 3.811 1.455 1.086 to 1.948
Rubis et al. 2012 [21] 0.877 0.559 to 1.376 1.399 0.908 to 2.157 1.200 0.914 to 1.577
Wu et al. 2012 [20] 0.903 0.763 to 1.069 1.365 1.100 to 1.693 1.145 1.021 to 1.285
Abbas et al. 2010 [19] 0.997 0.897 to 1.108 1.046 0.949 to 1.153 1.020 0.958 to 1.085
Taheri et al. 2010 [18] 0.909 0.343 to 2.411 0.996 0.414 to 2.395 1.029 0.596 to 1.774
Cizmarikova et al. 2010 [17] 0.586 0.350 to 0.980 1.613 0.946 to 2.753 1.471 1.066 to 2.030
Tatari et al. 2009 [16] 0.963 0.427 to 2.173 1.288 0.669 to 2.479 1.122 0.738 to 1.705
George et al. 2009 [15] 0.362 0.144 to 0.915 1.857 0.953 to 3.618 1.782 1.119 to 2.838
Henriquez-Hernandez et al. 2009 [14] 0.889 0.562 to 1.408 1.307 0.792 to 2.158 1.142 0.856 to 1.522
Turgut et al. 2007 [13] 0.249 0.093 to 0.663 1.936 0.773 to 4.848 2.051 1.189 to 3.541
Nordgard et al. 2007 [12] 0.580 0.245 to 1.371 0.949 0.533 to 1.688 1.105 0.738 to 1.653
Total (fixed effects) 0.952 0.882 to 1.028 0.209 1.110 1.027 to 1.200 0.008 1.059 1.010 to 1.111 0.017
Total (random effects) 0.907 0.767 to 1.073 0.250 1.181 0.973 to 1.434 0.093 1.098 0.972 to 1.240 0.133
Test for heterogeneity Q = 35.1721
DF = 15








I2 = 69.04 %
Ph < 0.0001
Values in italic are statistically significant (P value <0.05); Random effects model was used when Ph < 0.05 otherwise fixed effects model was used
CC homozygous wild-type, CT heterozygous, TT homozygous mutant, OR Odd Ratio, CI Confidence Interval, Q chi-squared statistic, DF degrees of freedom;
I2: percentage of total variation across studies due to heterogeneity; Ph: P value of Q test for heterogeneity test
Tazzite et al. BMC Genetics  (2016) 17:126 Page 7 of 11
On the other hand, Wu et al. [20] observed that patients
with a negative status of ER and PR have more CT + TT
genotypes than CC genotype (P = 0.013).
In second place, we tried through the present study to
evaluate the association between the ABCB1 C3435T
polymorphism and breast cancer risk through a meta-
analysis involving 16 studies with 6,094 cases of breast
cancer and 8,646 controls. Our meta-analysis suggests
that the ABCB1 C3435T polymorphism has no effect on
breast cancer development. It is noteworthy that a lack
of homogeneity between studies was observed regarding
the distribution of ABCB1 C3435T polymorphism.
This heterogeneity might be explained by ethnicity
variability and sample size across the different studies
included in the present meta-analysis. Indeed, Wang et
al. in a meta-analysis observed significant heterogen-
eity among the total studies, but not in the small size
sample analysis [38].
A number of meta-analysis were undertaken to assess
the association between ABCB1 C3435T polymorphism
and risk of breast cancer [38–41]. The first meta-
analysis conducted in 2011 which included 7 studies for
ABCB1 C3435T polymorphism did not show any asso-
ciation between this polymorphism and risk of breast
cancer [38]. However, it should be noted some errors in
C3435T genotypes reported for the study of Nordgard
et al. [12] and George et al. [15] which probably would
have influenced the study results [42].
A meta-analysis conducted two years later [38], en-
rolled 10 case-control studies with 5,282 cases and 7,703
controls, indicated that this polymorphism were associ-
ated with a significantly increased risk of breast cancer
according to the following models TT vs. CC (P = 0.003);
TT vs. CT + CC (P = 0.003) and TT + CT vs. CC (P =
0.029). Although our study was based on the same data
of the previous meta-analysis [38], we did not find any
significant association between the C3435T polymorph-
ism and risk of breast cancer. This can be explained by
the fact that we have added the results from other popu-
lations with different genetic background, such as North
Africa (Morocco, Egypt), Middle East (Jordan) and also
mixed populations (Mexico). In Morocco, for example,
the frequency of the wild-type 3435CC genotype was
found to be higher than that observed in Caucasians and
Asians. Conversely, the frequency of the mutated
homozygous variant was lower compared to the same
populations. However, similar results were reported in
Egypt which may be attributed probably to their com-
mon ethnic and geographic origins [37].
Thereby, we stratified our meta-analysis by ethnicity to
get a better idea about the involvement of this poly-
morphism in breast cancer risk. Our findings indicate
that patients with TT genotype had a significantly in-
creased risk of breast cancer in Asians, Caucasians and
North African but not among mixed populations. These
might be due to the differences in genetic background
Fig. 1 Forest plot of the relationship between ABCB1 C3435T polymorphism and breast cancer risk (T vs. C). The black squares correspond to the
odds ratios of the individual studies. The areas of squares are proportional to the study weight. The horizontal lines represent 95 % confidence
intervals. The diamonds represent the pooled odd ratios with 95 % confidence intervals
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and lifestyle and seem to confirm that the C3435T
polymorphism of ABCB1 gene varies across different
populations [43].
Conclusions
To the best of our knowledge, this is the first study,
which examined the association of ABCB1 C3435T poly-
morphism with the risk of breast cancer in a sample of
the Moroccan population. The results of the present
study revealed no difference between breast cancer pa-
tients and controls for ABCB1 C3435T polymorphism.
In addition, we did not find a significant correlation
between this polymorphism and clinicopathological
features of breast cancer patients. This may be explained
by the limited statistical power due to our small sample
size. It is also necessary to remember that there are
other polymorphisms in the ABCB1 gene implicated in
the etiology of breast cancer which also deserve to be
studied. Therefore, the results of the present study must
be interpreted with caution and cannot be generalized.
Larger case-control study, with at least 340 breast cancer
patients and 340 healthy controls, including more poly-
morphisms of ABCB1 with haplotype analysis is needed
to approve or not our conclusions and to obtain more
clear information about the influence of ABCB1 genetic
variants in breast cancer risk in Morocco. Moreover, it
would also be interesting to study the association of this
polymorphism with chemotherapy resistance in breast
cancer in our population. Furthermore, the results
obtained from the meta-analysis demonstrated that
the implication of C3435T variant on the risk of breast
cancer risk was modulated by ethnicity.
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